SEARCH

SEARCH BY CITATION

References

  • 1
    Copeland R.A., Harpel M.R., Tummino P.J. (2007) Targeting enzyme inhibitors in drug discovery. Expert Opin Ther Targets;11:967978.
  • 2
    Knight Z.A., Shokat K.M. (2005) Features of selective kinase inhibitors. Chem Biol;12:621637.
  • 3
    Copeland R.A. (2000) Enzymes, a Practical Introduction to Structure, Mechanism and Data Analysis, 2nd edn. New York, NJ, USA. John Wiley & sons Inc.
  • 4
    Krishnaswamy S. (2005) Exosite-driven substrate specificity and function in coagulation. J Thromb Haemost;3:5467.
  • 5
    Bode W., Schwager P. (1975) The refined crystal structure of bovine beta-trypsin at 1.8 A resolution. II. Crystallographic refinement, calcium binding site, benzamidine binding site and active site at pH 7.0. J Mol Biol;98:693717.
  • 6
    Krishnaswamy S., Betz A. (1997) Exosites determine macromolecular substrate recognition by prothrombinase. Biochemistry;36:1208012086.
  • 7
    Wilkens M., Krishnaswamy S. (2002) The contribution of factor Xa to exosite-dependent substrate recognition by prothrombinase. J Biol Chem;277:93669374.
  • 8
    Baugh R.J., Dickinson C.D., Ruf W., Krishnaswamy S. (2000) Exosite interactions determine the affinity of factor X for the extrinsic Xase complex. J Biol Chem;275:2882628833.
  • 9
    Pedicord D.L., Seiffert D., Blat Y. (2004) Substrate-dependent modulation of the mechanism of factor XIa inhibition. Biochemistry;43:1188311888.
  • 10
    Sun Y., Gailani D. (1996) Identification of a factor IX binding site on the third apple domain of activated factor XI. J Biol Chem;271:2902329028.
  • 11
    Tian G., Sobotka-Briner C.D., Zysk J., Liu X., Birr C., Sylvester M.A., Edwards P.D., Scott C.D., Greenberg B.D. (2002) Linear non-competitive inhibition of solubilized human gamma-secretase by pepstatin A methylester, L685458, sulfonamides, and benzodiazepines. J Biol Chem;277:3149931505.
  • 12
    Esler W.P., Kimberly W.T., Ostaszewski B.L., Ye W., Diehl T.S., Selkoe D.J., Wolfe M.S. (2002) Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate. Proc Natl Acad Sci U S A;99:27202725.
  • 13
    Rebholz K.L., Northrop D.B. (1995) Kinetics of iso mechanisms. Methods Enzymol;249:211240.
  • 14
    Rebholz K.L., Northrop D.B. (1994) Kinetics of enzymes with iso-mechanisms: dead-end inhibition of fumarase and carbonic anhydrase II. Arch Biochem Biophys;312:227233.
  • 15
    Toulokhonova L., Metzler W.J., Witmer M.R., Copeland R.A., Marcinkeviciene J. (2003) Kinetic studies on beta-site amyloid precursor protein-cleaving enzyme (BACE). Confirmation of an iso mechanism. J Biol Chem;278:45824589.
  • 16
    Swinney D.C. (2004) Biochemical mechanisms of drug action: what does it take for success? Nat Rev Drug Discov;3:801808.
  • 17
    Tummino P.J., Copeland R.A. (2008) Residence time of receptor-ligand complexes and its effect on biological function. Biochemistry;47:54815492.
  • 18
    Walker M.C., Kurumbail R.G., Kiefer J.R., Moreland K.T., Koboldt C.M., Isakson P.C., Seibert K., Gierse J.K. (2001) A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors. Biochem J;357:709718.
  • 19
    Jarman M., Barrie S.E., Llera J.M. (1998) The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors. J Med Chem;41:53755381.
  • 20
    Liu S., Zeng L.F., Wu L., Yu X., Xue T., Gunawan A.M., Long Y.Q., Zhang Z.Y. (2008) Targeting inactive enzyme conformation: aryl diketoacid derivatives as a new class of PTP1B inhibitors. J Am Chem Soc;130:1707517084.
  • 21
    Bogoyevitch M.A., Fairlie D.P. (2007) A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov Today;12:622633.
  • 22
    Monder C., Lakshmi V., Miroff Y. (1991) Kinetic studies on rat liver 11 beta-hydroxysteroid dehydrogenase. Biochim Biophys Acta;1115:2329.
  • 23
    Sahni-Arya B., Flynn M.J., Bergeron L., Salyan M.E., Pedicord D.L., Golla R., Ma Z. et al. (2007) Cofactor-specific modulation of 11beta-hydroxysteroid dehydrogenase 1 inhibitor potency. Biochim Biophys Acta;1774:11841191.
  • 24
    Tu H., Powers J.P., Liu J., Ursu S., Sudom A., Yan X., Xu H. et al. (2008) Distinctive molecular inhibition mechanisms for selective inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1. Bioorg Med Chem;16:89228931.
  • 25
    Wilson D.K., Tarle I., Petrash J.M., Quiocho F.A. (1993) Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat. Proc Natl Acad Sci U S A;90:98479851.
  • 26
    Freymann D.M., Wenck M.A., Engel J.C., Feng J., Focia P.J., Eakin A.E., Craig S.P. (2000) Efficient identification of inhibitors targeting the closed active site conformation of the HPRT from Trypanosoma cruzi. Chem Biol;7:957968.
  • 27
    Yuan L., Craig S.P. III, McKerrow J.H., Wang C.C. (1992) Steady-state kinetics of the schistosomal hypoxanthine-guanine phosphoribosyltransferase. Biochemistry;31:806810.
  • 28
    Dessauer C.W., Gilman A.G. (1997) The catalytic mechanism of mammalian adenylyl cyclase. Equilibrium binding and kinetic analysis of P-site inhibition. J Biol Chem;272:2778727795.
  • 29
    Ward N.E., O’Brian C.A. (1992) Kinetic analysis of protein kinase C inhibition by staurosporine: evidence that inhibition entails inhibitor binding at a conserved region of the catalytic domain but not competition with substrates. Mol Pharmacol;41:387392.
  • 30
    Xu Z.B., Chaudhary D., Olland S., Wolfrom S., Czerwinski R., Malakian K., Lin L., Stahl M.L., Joseph-McCarthy D., Benander C., Fitz L., Greco R., Somers W.S., Mosyak L. (2004) Catalytic domain crystal structure of protein kinase C-theta (PKCtheta). J Biol Chem;279:5040150409.
  • 31
    Prade L., Engh R.A., Girod A., Kinzel V., Huber R., Bossemeyer D. (1997) Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential. Structure;5:16271637.
  • 32
    Zheng J., Trafny E.A., Knighton D.R., Xuong N.H., Taylor S.S., Ten Eyck L.F., Sowadski J.M. (1993) 2.2 A refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor. Acta Crystallogr D Biol Crystallogr;49:362365.
  • 33
    Karni R., Mizrachi S., Reiss-Sklan E., Gazit A., Livnah O., Levitzki A. (2003) The pp60c-Src inhibitor PP1 is non-competitive against ATP. FEBS Lett;537:4752.
  • 34
    Schindler T., Sicheri F., Pico A., Gazit A., Levitzki A., Kuriyan J. (1999) Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol Cell;3:639648.
  • 35
    Kovalenko M., Ronnstrand L., Heldin C.H., Loubtchenkov M., Gazit A., Levitzki A., Bohmer F.D. (1997) Phosphorylation site-specific inhibition of platelet-derived growth factor beta-receptor autophosphorylation by the receptor blocking tyrphostin AG1296. Biochemistry;36:62606269.